MD Anderson Ovarian SPORE publications – 2003
1.
Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R,
Urban N, Orsulic S, Smyth J. Current research and treatment for epithelial ovarian cancer. A
Position Paper from the Helene Harris Memorial Trust. Eur J Cancer 39(13):1818-27, 2003. PMID:
12932658.
2.
Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10 Suppl):200s5s, 2003. PMID: 12743135.
3.
Bast RC Jr, Mills GB. General keynote: molecular therapeutics and pharmocogenomics. Gynecol
Oncol 88(1 Pt 2):S84-7; discussion S93-6, 2003. PMID: 12586093.
4.
Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga
CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the
antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22(18):2812-22, 2003. PMID:
12743604.
5.
Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM. Phase II
trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin
Oncol 21(2):291-7, 2003. PMID: 12525521.
6.
Boling W, Fouladi RT, Basen-Engquist K. Health-related quality of life in gynecological oncology:
instruments and psychometric properties. Int J Gynecol Cancer 13(1):5-14, 2003. PMID: 12631213.
7.
Brewer MA, Johnson K, Follen M, Gershenson D, Bast R, Jr. Prevention of ovarian cancer:
intraepithelial neoplasia. Clin Cancer Res 9(1):20-30, 2003. PMID: 12538447.
8.
Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB. Vascular
endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic
vascular remodeling in an ovarian cancer model. Clin Cancer Res 9(15):5721-8, 2003. PMID:
14654557.
9.
Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ,
Markman M, McGuire WP, 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L.
Progress in the management of gynecologic cancer: consensus summary statement. J Clin
Oncol 21(10 Suppl):129s-32s, 2003. PMID: 12743127.
10.
Cao SN, Chang KH, Luthra R, Liu J. Frameshift mutations in the bax gene are not involved in
development of ovarian endometrioid carcinoma. Mod Pathol 16(10):1048-52, 2003. PMID:
14559989.
11.
Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy.
Drug Resist Updat 6(3):129-36, 2003. PMID: 12860460.
12.
Deavers MT, Malpica A, Liu J, Broaddus R, Silva EG. Ovarian sex cord-stromal tumors: an
immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol
16(6):584-90, 2003. PMID: 12808064.
13.
Deavers MT, Malpica A, Ordonez NG, Silva EG. Ovarian steroid cell tumors: an
immunohistochemical study including a comparison of calretinin with inhibin. Int J Gynecol
Pathol 22(2):162-7, 2003. PMID: 12649671.
14.
Fidler IJ, Yoneda J, Herrera C, Wood J, Xu L. Specific keynote: molecular determinants of
angiogenesis in ovarian cancer. Gynecol Oncol 88(1 Pt 2):S29-36; discussion S7-42, 2003. PMID:
12586082.
15.
Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II study of oxaliplatin in
platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol
21(15):2856-9, 2003. PMID: 12885801.
16.
Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair
gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer
98(10):2199-206, 2003. PMID: 14601090.
17.
Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K, Berchuck A, Pinkel D, Albertson
D, Mills GB. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol
Oncol 88(1 Pt 2):S16-21; discussion S2-4, 2003. PMID: 12586079.
18.
Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R,
Schrier AD, Lynch KR, Mills GB, Fang X. Identification of a phosphothionate analogue of
lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem
278(14):11962-9, 2003. PMID: 12554733.
19.
Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B. Cell to cell contact required for bystander
effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol 22(6):1241-5, 2003.
PMID: 12738989.
20.
Hung MC, Wu HS, Kao CH, Chen WK, Changlai SP. F18-fluorodeoxyglucose positron emission
tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum
thyroglobulin levels but negative I-131 whole body scan. Endocr Res 29(2):169-75, 2003. PMID:
12856803.
21.
Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu
ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol
Carcinog 36(2):53-9, 2003. PMID: 12557260.
22.
Kabbani W, Deavers MT, Malpica A, Burke TW, Liu J, Ordonez NG, Jhingran A, Silva EG. Uterine
tumor resembling ovarian sex-cord tumor: report of a case mimicking cervical adenocarcinoma.
Int J Gynecol Pathol 22(3):297-302, 2003. PMID: 12819400.
23.
Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS,
Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian
cancer. Clin Cancer Res 9(13):4782-91, 2003. PMID: 14581349.
24.
Kohn EC, Mills GB, Liotta L. Promising directions for the diagnosis and management of
gynecological cancers. Int J Gynaecol Obstet 83 Suppl 1:203-9, 2003. PMID: 14763176.
25.
Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN,
Malpica A, Gershenson DM, Hung MC, Lu KH. beta-catenin nuclear localization is associated with
grade in ovarian serous carcinoma. Gynecol Oncol 88(3):363-8, 2003. PMID: 12648588.
26.
Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates
radioresistance. Int J Radiat Oncol Biol Phys 57(1):246-54, 2003. PMID: 12909240.
27.
Liao Y, Hung MC. Regulation of the activity of p38 mitogen-activated protein kinase by Akt in
cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol
23(19):6836-48, 2003. PMID: 12972603; PMCID: PMC193925.
28.
Liotta LA, Petricoin EF, 3rd, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB,
Simone C, Fishman DA, Kohn EC. General keynote: proteomic patterns in sera serve as
biomarkers of ovarian cancer. Gynecol Oncol 88(1 Pt 2):S25-8; discussion S37-42, 2003. PMID:
12586081.
29.
Lu Y, Wang H, Mills GB. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol
7(2):205-28, 2003. PMID: 14763163.
30.
Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills
GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate
phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278(41):40057-66, 2003. PMID:
12869565.
31.
Ludes-Meyers JH, Bednarek AK, Popescu NC, Bedford M, Aldaz CM. WWOX, the common
chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 100(1-4):101-10, 2003.
PMID: 14526170.
32.
Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small
G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers.
Oncogene 22(19):2897-909, 2003. PMID: 12771940.
33.
Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M,
Sood AK. Stress-related mediators stimulate vascular endothelial growth factor secretion by two
ovarian cancer cell lines. Clin Cancer Res 9(12):4514-21, 2003. PMID: 14555525.
34.
Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX.
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand
induction and cell death in ovarian carcinoma cells. J Biol Chem 278(21):19245-56, 2003. PMID:
12637505.
35.
Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX. Cisplatin resistance in an ovarian carcinoma
is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res
13(6-10):399-404, 2003. PMID: 12725530.
36.
Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW,
Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Specific
keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol 88(1 Pt 2):S88-92; discussion
S3-6, 2003. PMID: 12586094.
37.
Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking
molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Semin Oncol 30(5 Suppl 16):93-104, 2003. PMID: 14613030.
38.
Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer
3(8):582-91, 2003. PMID: 12894246.
39.
Najafi SM, Li Z, Makino K, Shao R, Hung MC. The adenoviral E1A induces p21WAF1/CIP1
expression in cancer cells. Biochem Biophys Res Commun 305(4):1099-104, 2003. PMID:
12767945.
40.
Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B,
Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ. NY-ESO1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial
ovarian cancer. Cancer Res 63(18):6076-83, 2003. PMID: 14522938.
41.
Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC Jr, Brewer MA. Specific keynote:
chemoprevention of ovarian cancer: the journey begins. Gynecol Oncol 88(1 Pt 2):S59-66;
discussion S7-70, 2003. PMID: 12586088.
42.
Pask AJ, Behringer RR, Renfree MB. Expression of DMRT1 in the mammalian ovary and testis-from marsupials to mice. Cytogenet Genome Res 101(3-4):229-36, 2003. PMID: 14684988.
43.
Qian L, Xu Y, Hasegawa Y, Aoki J, Mills GB, Prestwich GD. Enantioselective responses to a
phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist
activity. J Med Chem 46(26):5575-8, 2003. PMID: 14667211.
44.
Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC,
Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in
ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98(4):758-64, 2003.
PMID: 12910520.
45.
See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current
status and future prospects. Int J Gynecol Cancer 13(6):701-34, 2003. PMID: 14675307.
46.
Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, Burt RW, Ellis PR, Mathias CJ,
Green MA, Gershenson DM. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic
agent for ovarian cancer: initial clinical results. J Nucl Med 44(5):700-7, 2003. PMID: 12732670.
47.
Silva EG, Deavers MT, Parlow AF, Gershenson DM, Malpica A. Calcifications in ovary and
endometrium and their neoplasms. Mod Pathol 16(3):219-22, 2003. PMID: 12640101.
48.
Skates S, Troiano R, Knapp RC. Longitudinal CA125 detection of sporadic papillary serous
carcinoma of the peritoneum. Int J Gynecol Cancer 13(5):693-6, 2003. PMID: 14675358.
49.
Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ. Calculation of
the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal
women. J Clin Oncol 21(10 Suppl):206s-10s, 2003. PMID: 12743136.
50.
Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann
LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA,
Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in
accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 9(10 Pt 1):3534-45,
2003. PMID: 14506139.
51.
Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA,
Felix EA, Atkinson EN, Mills GB. The human lipid phosphate phosphatase-3 decreases the growth,
survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid
signaling cascade as a target for therapy in ovarian cancer. Cancer Res 63(5):1073-82, 2003.
PMID: 12615725.
52.
Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka
AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and
xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 9(2):845-52,
2003. PMID: 12576458.
53.
Wang L, Deavers MT, Malpica A, Silva EG, Liu J. Tissue macroarray: a simple and cost-effective
method for high-throughput studies. Appl Immunohistochem Mol Morphol 11(2):174-6, 2003. PMID:
12778004.
54.
Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC Jr, Yu
Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of
breast cancer. Clin Cancer Res 9(10 Pt 1):3660-6, 2003. PMID: 14506155.
55.
Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick
GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian
cancers. Gynecol Oncol 88(1):73-9, 2003. PMID: 12504632.
56.
Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated
siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian
cancer. Oncogene 22(36):5694-701, 2003. PMID: 12944918.
57.
Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC Jr.
Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci 983:268-77,
2003. PMID: 12724231.
58.
Zhou C, Liu J. Inhibition of human telomerase reverse transcriptase gene expression by BRCA1
in human ovarian cancer cells. Biochem Biophys Res Commun 303(1):130-6, 2003. PMID:
12646176.
59.
Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation
in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22(16):2396-404, 2003.
PMID: 12717416.